List view / Grid view
The future of drug discovery lies in an automated world where the workflows for biological assays, chemical synthesis and data analysis are connected by flexible, mobile and modular hardware, integrated with software solutions that will interface with scientists for increased efficiency and productivity (the realisation of Industry 4.0). This article…
Scripps Research has announced it will screen over 14,000 compounds to see if any present significant activity against COVID-19, for use in a therapeutic.
The National Drug Discovery Centre (NDDC) has opened in Australia, with support from the government to subsidise the screening of medicinal compounds.
The first drug designed using artificial intelligence (AI) has moved into its Phase I trial. Professor Andrew Hopkins of Exscientia explains how an algorithm was used to achieve this milestone.
Dr Nicolas Poirier reveals how immunotherapies can be designed to recalibrate the immune system for long-term maintenance of autoimmune remission.
25 February 2020 | By Bruker Daltonics
Register for our latest webinar supported by Bruker Daltonics to get an overview of the SPR user and application landscape in 2020. During the one-hour session, you will learn about the latest software tools for Bruker’s SPR instrumentation and explore high-throughput screening strategies enabled by the Bruker SPR ecosystem.
Read how Cyto-Mine® has helped improve overall efficiency and productivity in cell line development at FUJIFILM Diosynth Biotechnologies.
Hybridoma-based antibody discovery: the challenges and how to overcome them using microfluidic picodroplet technology.
In vitro evaluation of hepatic function using a primary human hepatocyte 3D spheroid culture system
Hypoxia measurements in live and fixed cells using fluorescence microscopy and high-content imaging
A new technology developed by scientists combines small molecule screening methods with machine learning algorithms to identify novel antibiotics that inhibit ribosomes.
A new technique has been developed which has the potential to harness bacteria to produce billions of different drug candidates to treat diseases like cancer.
There is room for improvement in the production of monoclonal antibodies; commercial production needs increased process efficiency and reduced costs.
Current trends in the development of therapeutic biologics suggest that engineered molecules such as bispecific antibodies and antibody-drug conjugates are the future of the industry, yet despite this, monoclonal antibody (mAb) development remains a dominant focus.
A library of products derived from more than 10,000 fungi has been established which could lead to the discovery of new drugs.
